Table 2. . Anti-CD19 chimeric antigen receptor T cell studies in mantle cell lymphoma and follicular lymphoma.
| Trial/study | ZUMA-2 [33] | TRANSCEND-NHL001 [54] | UPenn [36] | FHCRC [58] | ZUMA-5 [59] | ELARA |
|---|---|---|---|---|---|---|
| Disease | MCL | MCL | FL | FL | FL/MZL | FL |
| CAR T product | KTE-X19 | Liso-cel | Tisa-cel | 1:1 CD4+/CD8 4–1BB CART | Axi-cel | Tisa-cel |
| Patients apheresed (evaluable) | 74 (68) | 25 (17) | 16 (14) | 8 | 127 (80) | 97 (52) |
| Median F/U (months) | 12.3 | 8.4 | 28.6 | 24 | 15.3 | NA |
| ORR (CR) % | 93 (67) | 71 (53) | 79 (71) | 100 (88) | 93 (80) | 82.7 (65.4) |
| Median PFS (months) | NR | 5.8 | NR | NR | 23.5 | NR |
| Median OS (months) | NR | 11.1 | NR | NR | NR | NR |
| CRS (any grade) CRS ≥3 |
91% 15% |
41% 6% |
57%† 18%† |
59% 0 |
77% 7% |
48.5% 0 |
| Median onset CRS, days (range) | 2 (1–13) | 7 (2–10) | NA | NA | 4 (1–15) | 4 (1–14) |
| NT (any grade) NT ≥3 |
63% 31% |
18% 12% |
39%† 11%† |
50% 0 |
55% 15% |
9.3% 1% |
| Median onset NT, days (range) | 7 (1–32) | 9 (7–25) | NA | NA | 7 (1–177) | 8.5 (4–190) |
†
Data of CRS and NT available for the whole group (diffuse large B-cell lymphoma and FL).
CAR T: Chimeric antigen receptor T cell; CR: Complete response; CRS: Cytokine release syndrome; FHCRC: Fred Hutchinson Cancer Research Center; FL: Follicular lymphoma; MCL: Mantle cell lymphoma; MZL: Marginal zone lymphoma; NA: Not available; NR: Not reached; NT: Neurotoxicity; ORR: Overall response rate; OS: Overall survival; PFS: Progression-free survival; UPenn: University of Pennsylvania.